Photo: News 18
DCGI Grants EUA For 2 Doses Of ZyCoV-D, COVID Vaccine For Children
The Drugs Controller General of India granted Emergency Use Authorization (EUA) of two doses of ZyCoV-D, a COVID-19 vaccine for children above 12 years old. Manufactured by Zydus Lifesciences limited, the vaccine was used in three doses, for 0,28, and 56 days. However, with the recent approval, ZyCoV-D would now be used in two doses, with a gap of 0-28 days. With this, vaccination time required will be reduced.
Tags: ZyCoV-D Vaccine, Covid-19 Vaccine, DCGI, children, Time Gap
Courtesy: ANI
Photo: The Times Of India
DCGI Approves Covaxin For Children Between 6-12 Year Old, Corbevax For EUA
The Drugs Controller General of India (DCGI) approved the two vaccines Covaxin and Corbevax for children under 12 in India, against COVID-19. While Bharat Biotech's Covaxin has been approved for 6 to12-year-old, Biological E's Corbevax will be used as Emergency Use Authorization (EUA) for 5 to12-year-old kids in India. The approval was based on the Subject Expert Committee's recommendation report, which was prepared as per trials of the… read-more
Tags: Covaxin, covid-19 vaccines, DCGI, Corbevax, children
Courtesy: The Free Press Journal
Photo: Hindustan Times
SEC Recommends Corbevax COVID-19 Vaccine For 5-12 Year Old
The Subject Expert Committee (SEC) or the Drugs Controller General of India (DCGI) recommended the Corbevax COVID-19 vaccine for children between the 5 to 12-year-old age group. On April 21, the government panel said the vaccine is effective in children and has been recommended after trials. Furthermore, the final approval for the emergency use authorization (EUA) of Corbevax would be given by the DCGI soon.
Tags: Corbevax, Covid-19, DCGI, Delhi, children
Courtesy: ANI
Photo: ABP News
Glenmark Launches Nitric Oxide Nasal Spray For COVID-19 Patients In India
Amid COVID-19 pandemic, India is to have Nitric Oxide Nasal Spray, for adults having the infection. Launched on February 9 by Glenmark Pharmaceutical, the spray would be for adults, contracting the virus, with high-risk of progression of the disease. The medicine has been launched under FabiSpray brand in India. In July 2021, Glenmark proposed the nasal Spray, which later got approved by the Drugs Controller Genera of India (DCGI).
Tags: Covid-19, Nasal Spray, glenmark pharmaceuticals, Central Government, DCGI
Courtesy: The Free Press Journal
Photo: Hindustan Times
Human Trials Of mRNA, India's Vaccine Against Omicron To Begin In February
Human trials of mRNA vaccine against COVID-19's new variant Omicron is to begin from February. Notably, Pune-based Gennova Biopharmaceutical made mRNA vaccine and completed phase I and II trials and submitted a report to the Drugs Controller General of India (DCGI). Along with it, the company also submitted a data of Phase III trials and are waiting for their approval from the Vaccine Subject Expert Committee (SEC).
Tags: mRNA, Omicron Vaccine, Gennova biopharmaceutical, Covid-19, DCGI
Courtesy: The Times Of India
Photo: The Statesman
DCGI Approves India Made RT-PCR Kit To Detect Omicron
The Director Controller General of India (DCGI) approved India made RT-PCR kit to detect new COVID-19 variant "Omicron". On January 5, ICMR General Director Dr Balram Bhagava said, the new RT-PCR kit has been manufactured by Tata MD and ICMR, to test Omicron. "This kit test will give results in four hours," said Dr. Bhagava. Meanwhile, in India, there are a total of 2,135 Omicron cases.
Tags: omicron, DCGI, ICMR, Dr Balram Bhargav, RT-PCR Kit
Courtesy: ANI
Photo: Bharat Biotech Website
DCGI Approves Phase III Trial Of Bharat Biotech's Intranasal COVID-19 Vaccine
The Director Control General of India (DCGI) approved phase III trial of Intranasal COVID-19 vaccine, manufactured by Bharat Biotech. On January 4, the Subject Expert Committee (SEC) of the DCGI, approved the report, following which phase III trail will begin on 5,000 subject, 50% Covishield vaccinated people and 50% COVAXIN vaccinated people. If successful, the Intranasal vaccine will be used as booster shot, especially when nation is facing… read-more
Tags: Bharat biotech, DCGI, Intranasal vaccine, Covid-19, omicron
Courtesy: One India
Photo: Business Standard
DCGI Gives Nod To Bharat Biotech For Administering Covaxin To Kids
Hyderabad-based Bharat Biotech was granted emergency approval to administer the COVID-19 vaccine to kids between the age of 12 to 18 years by the Drug Controller General of India (DCGI), on December 25. Reportedly, the company has further started the regulatory process to make it available on CoWin platform. Biotech's vaccine has become the second vaccine to receive approval after Zydus Cadila's three-dose needle-free vaccine ZyCoV-D in India… read-more
Tags: Covaxin, Bharat biotech, DCGI, approval, kids
Courtesy: Money Control
Photo: The Economic Times
Hyderabad's Bharat Biotech Seeks Phase 3 Trial Of Intranasal Vaccine Booster Shot
Hyderabad based Bharat Biotech, on December 20, sough approval for phase 3 trial of its COVID-19 booster shot. The company urged the DCGI to approve trials for intranasal vaccine against COVID-19, especially amid Omicron scare. "The application has been filed and the company is awaiting approval from the drug regulator," reported PTI. Notably, the company already conducted phase I and phase II trials and submitted a detailed report… read-more
Tags: Intranasal vaccine, Covid-19, Bharat biotech, DCGI, Omicron Strain
Courtesy: The Indian Express
Photo: Firstpost
Bharat Biotech Awaits Approval To Roll Out Covaxin To Children Aged 2-8 Yrs
Bharat Biotech after submitting vaccine trial reports of "Covaxin" amongst beneficiaries aged between 2-8 years, said that they are awaiting the approval from the drug regulators. Upon receiving approval, Covaxin will become "one of the first vaccines in the world" to be administered to beneficiaries belonging to the said age group. After reviewing the results, the Subject Expert Committee (SEC) recommended the grant of the vaccine.
Tags: Bharat biotech, Covaxin, DCGI, Vaccine Trial
Courtesy: ANI News
